Profile Picture
Rewards
  • All
  • Chat
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Unveils new gun safety office
1st maternal RSV vaccine
Kills relatives in crash
Husband has lung cancer
‘Didn’t want to go this thin’
Executed for 1996 killing
Confirm romance with kiss
Ribeiro suffers concussion
DA investigator shoots self
Nuke test-site activity rises
Ukraine attacks Crimea HQ
Amazon Prime Video ads
McD to raise royalty fees
Retires after 11 seasons
Megan Rapinoe's legacy
Black Music Action Coalition
Cold treats to cool down
Mass. state-funded housing
Reds release Renfroe
Israel-Saudi peace deal
Rugby World Cup 2023
Joins 40-40 club
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
222,000 results
朝日新聞社8d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 ... WASHINGTON--U.S. officials granted full approval to a closely watched Alzheimer’s drug on ...
Afro10d
Why is Medicare rationing Alzheimer’s drugs?
The FDA has recently approved exciting new treatments that can slow the progression of Alzheimer’s disease, a scourge that claims more American lives than breast cancer and prostate cancer combined.
2d
MIT’s A11 Drug: Reducing Inflammation and Enhancing Memory in Alzheimer’s Disease
A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...
New York Post29d
The FDA is now fast-tracking new drug approvals — why that’s so worrying
The Food and Drug Administration is now regularly approving new drugs after just one or two clinical trials — a significant departure from the more rigorous vetting process the agency was ...
8hon MSN
FDA advisory panel rejects drug-device combination to treat Type 2 diabetes
The vote essentially upheld the Food and Drug Administration’s earlier rulings, with some members calling for new clinical ...
1d
At special FDA hearing, Intarcia's twice-rejected drug-device combo gets another 'no'
An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.
Daily Trojan11d
The USC researchers behind a newly approved treatment for Alzheimer’s
USC researchers played a key role in a new treatment for Alzheimer’s disease, the first with full approval to target a suspected root cause of the condition, offering hope to those with the disease ...
Salon9d
Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?
For decades, attempts to treat or slow Alzheimer's disease (AD) — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting ...
BioPharma Dive
1d
Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
PBS11d
All You Need to Know About Alzheimer's
Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add ...
WTOP News9d
New Treatments for Alzheimer’s Disease
For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.
Washington Monthly
10d
As Dementia Cases Soar, Who Will Care for the Caregivers?
A CMS pilot project will test a low-cost way to help families support a suffering loved one. It’s more promising than ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices